Session Information

 x 
My Library Virtual Library FAQ

  • WCLC 2022

    2022 World Conference on Lung Cancer

    As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.

    Presentation Date(s):  
    • August 6 - 9, 2022
    • Total Presentations: 2015

    All times listed are in Vienna, Austria Time, CEST (UTC+2:00)

    PL - Plenary
    IBS - Interactive Breakfast Session (in-person attendees only)
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    P - Posters
    EP - ePosters
    WS - Workshops
    LA – Lectureship Awards
    IS - Industry Symposium

    Switch to Virtual Meeting
    Enter Virtual Meeting Access Code
Filter Results:

Show Only CME Accredited Sessions

  • +

    EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      EP08.02-118 - TRUST-II: A Global Phase II Study for Taletrectinib inROS1fusion Positive Lung Cancer and Other Solid Tumors

      Presenter: Misako Nagasaka

      • Abstract

      Loading...

  • +

    EP16.03 - Tumor Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Tumor Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics
    • +

      EP16.03-021 - Developing of EGFR resistant mutations to Tyrosine Kinase Inhibitors (TKI) in Non-Small Cell Lung Cancer (NSCLC)

      Presenter: Luis Raez, MD, FACP, FCCP

      • Abstract

      Loading...

  • +

    MA13 - Update on ROS1 Inhibitors and New Pathways

    • 12:00 - 13:00
    • 8/09/2022
    • Location: Hall C7
    • Not for CME Credit
    • Type: Mini Oral
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      MA13.08 - A Phase 1 Trial of Sapanisertib and Telaglenastat (CB-839) in Patients With Advanced NSCLC (NCI 10327): Results from Dose Escalation

      12:32 - 12:37  |  Presenter: Jonathan Riess

      • Abstract

      Loading...